Inverness Medical Innovations
This article was originally published in The Gray Sheet
Executive Summary
Acquisition of osteoporosis product maker Ostex in stock deal worth roughly $37 mil. rounds out the women's healthcare provider's intellectual property portfolio, firm says in Sept. 9 conference call. Inverness cites the Ostex NTx assay's increasing acceptance for management and monitoring of osteoporosis treatments as a primary driver of the deal...